EGFR wild-type + ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type + ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks (New A1) serplulimab Sensitive : A1 Henlius Press Release - 2wk	serplulimab Sensitive: A1 - Approval Henlius Press Release - 2 weeks serplulimab Sensitive : A1 Henlius Press Release - 2 weeks - (New A1)
EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2	rivoceranib Sensitive: C2 – Inclusion Criteria rivoceranib Sensitive : C2
EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	SI-B001 Sensitive: C2 – Inclusion Criteria SI-B001 Sensitive : C2	SI-B001 Sensitive: C2 – Inclusion Criteria SI-B001 Sensitive : C2
EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type	Non Small Cell Lung Cancer	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3	anlotinib Sensitive: C3 – Early Trials anlotinib Sensitive : C3
EGFR wild-type + ALK wild-type	Lung Adenocarcinoma	EGFR wild-type + ALK wild-type	Lung Adenocarcinoma	rivoceranib Sensitive: C4 – Case Studies rivoceranib Sensitive : C4	rivoceranib Sensitive: C4 – Case Studies rivoceranib Sensitive : C4

EGFR wild-type + ALK wild-type

Associations